CRYSTAL FORM OF MACROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF

The present invention relates to the technical field of drug synthesis. Disclosed are a crystal form of a macrocyclic compound, and a preparation method therefor and the use thereof. The macrocyclic compound is (6R, 16R)-9-fluoro-16-methyl-13-oxa-2,17,21,25-tetraazapentane [16.6.2.02,6.07,12.022,26]dihexadecane-1(25),7,9,11,18(26),19,21,23-octane-19-carbonitrile. The X-ray diffraction pattern of the crystal form has characteristic peaks at 2θ values of 9.49 ± 0.2, 10.60 ± 0.2, 11.54 ± 0.2, 14.10 ± 0.2, 17.09 ± 0.2, 19.15 ± 0.2, 20.30 ± 0.2, 22.85 ± 0.2, 23.89 ± 0.2, and 27.74 ± 0.2. The crystal form is hygroscopicity-free, and has a good stability and pharmacokinetic properties. La présente invention relève du domaine technique de la synthèse des médicaments. L'invention concerne une forme cristalline d'un composé macrocyclique, son procédé de préparation et son utilisation. Le composé macrocyclique est (6R, 16R)-9-fluoro-16-méthyl-13-oxa-2,17,21,25-tétraazapentane [16.6.2.02,6.07,12.022,26]dihexadécane-1(25)